Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration.
Özlem DikmetaşSibel KadayifcilarBora EldemUlkar FeyzullayevaPublished in: Northern clinics of Istanbul (2022)
Although the final visual outcome is limited by the progression of the disease, hemorrhagic lesions treated with ranibizumab have stable anatomical outcome.